1. |
Kumamoto T, Kurahashi Y, Niwa H, et al. True esophagogastric junction adenocarcinoma: Background of its definition and current surgical trends. Surg Today, 2020, 50(8): 809-814.
|
2. |
Yanagimoto Y, Kurokawa Y, Doki Y, et al. Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. Jpn J Clin Oncol, 2022, 52(5): 417-424.
|
3. |
Cao F, Hu C, Xu ZY, et al. Current treatments and outlook in adenocarcinoma of the esophagogastric junction: A narrative review. Ann Transl Med, 2022, 10(6): 377.
|
4. |
Nobel T, Molena D. Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg, 2019, 3(4): 390-395.
|
5. |
Zhang S, Orita H, Fukunaga T. Current surgical treatment of esophagogastric junction adenocarcinoma. World J Gastrointest Oncol, 2019, 11(8): 567-578.
|
6. |
Xiong W, Chen Y, Zhu X, et al. Transthoracic single-port assisted laparoscopic five-step maneuver lower mediastinal lymphadenectomy for Siewert typeⅡadenocarcinoma of the esophagogastric junction. Ann Surg Oncol, 2022, 29(6): 3936-3937.
|
7. |
Sugita S, Kinoshita T, Kuwata T, et al. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction. Surg Endosc, 2021, 35(1): 340-348.
|
8. |
陈龙奇, 胡建昆, 季加孚, 等. 食管胃结合部腺癌外科治疗中国专家共识 (2018年版). 中华胃肠外科杂志, 2018, 21(9): 961-975.
|
9. |
郑民华, 臧潞, 马君俊, 等. SiewertⅡ型食管胃结合部腺癌腔镜手术治疗中国专家共识 (2019版). 中国实用外科杂志, 2019, 39(11): 1129-1135.
|
10. |
李双喜, 李子禹. 食管胃结合部腺癌腹腔镜手术的下纵隔淋巴结清扫边界及质量控制. 中华胃肠外科杂志, 2022, 25(2): 120-123.
|
11. |
李珍艳, 顾一敏, 王文凭, 等. 从胸外科视角看SiewertⅡ型食管胃结合部腺癌的治疗. 中华胃肠外科杂志, 2022, 25(2): 109-113.
|
12. |
谭黎杰. 食管胃结合部腺癌经胸路径手术的利与弊. 中华胃肠外科杂志, 2022, 25(2): 147-150.
|
13. |
Oh SE, Lee GH, An JY, et al. Comparison of transabdominal and transthoracic surgical approaches in the treatment of Siewert type Ⅱ esophagogastric junction cancers: A propensity score-matching analysis. Eur J Surg Oncol, 2022, 48(2): 370-376.
|
14. |
Wu H, Shang L, Du F, et al. Transhiatal versus transthoracic surgical approach for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction: A meta-analysis. Expert Rev Gastroenterol Hepatol, 2020, 14(11): 1107-1117.
|
15. |
Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: Surgical therapy based on 1 602 consecutive resected patients. Surg Oncol Clin N Am, 2006, 15(4): 751-764.
|
16. |
Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: A prospective nationwide multicenter study. Ann Surg, 2021, 274(1): 120-127.
|
17. |
Peng J, Wang WP, Yuan Y, et al. Optimal extent of lymph node dissection for Siewert type Ⅱ esophagogastric junction adenocarcinoma. Ann Thorac Surg, 2015, 100(1): 263-269.
|
18. |
Blank S, Schmidt T, Heger P, et al. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG Ⅱ): Thoracoabdominal or abdominal approach? Gastric Cancer, 2018, 21(2): 303-314.
|
19. |
Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: Influence of esophageal resection margin and operative approach on outcome. Ann Surg, 2007, 246(1): 1-8.
|